NASDAQ: QNRX
Quoin Pharmaceuticals Ltd Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their QNRX stock forecasts and price targets.

Forecast return on equity

Is QNRX forecast to generate an efficient return?

Company
N/A
Industry
237.05%
Market
146.76%

Forecast return on assets

Is QNRX forecast to generate an efficient return on assets?

Company
N/A
Industry
106.33%

QNRX earnings per share forecast

What is QNRX's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$21.58
Avg 2 year Forecast
-$15.74
Avg 3 year Forecast
-$9.97

QNRX revenue forecast

What is QNRX's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$6.7M
Avg 3 year Forecast
$34.0M

QNRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
QNRX$11.30N/AN/A
SNSE$9.17$65.00+608.83%Buy
PHIO$2.05$14.00+582.93%Buy
LIXT$4.29N/AN/A
ETHZ$19.64N/AN/A

Quoin Pharmaceuticals Stock Forecast FAQ

What is QNRX's earnings growth forecast for 2025-2027?

(NASDAQ: QNRX) Quoin Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41.92%.

Quoin Pharmaceuticals's earnings in 2025 is -$12,169,276.On average, 5 Wall Street analysts forecast QNRX's earnings for 2025 to be -$444,168,102, with the lowest QNRX earnings forecast at -$530,377,441, and the highest QNRX earnings forecast at -$250,735,409. On average, 4 Wall Street analysts forecast QNRX's earnings for 2026 to be -$323,992,144, with the lowest QNRX earnings forecast at -$510,606,810, and the highest QNRX earnings forecast at -$119,963,924.

In 2027, QNRX is forecast to generate -$205,146,030 in earnings, with the lowest earnings forecast at -$197,101,088 and the highest earnings forecast at -$211,179,737.

If you're new to stock investing, here's how to buy Quoin Pharmaceuticals stock.

What is QNRX's revenue growth forecast for 2025-2027?

(NASDAQ: QNRX) Quoin Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.8%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.17%.

Quoin Pharmaceuticals's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast QNRX's revenue for 2025 to be $0, with the lowest QNRX revenue forecast at $0, and the highest QNRX revenue forecast at $0. On average, 4 Wall Street analysts forecast QNRX's revenue for 2026 to be $137,060,456, with the lowest QNRX revenue forecast at $0, and the highest QNRX revenue forecast at $282,190,558.

In 2027, QNRX is forecast to generate $699,177,130 in revenue, with the lowest revenue forecast at $320,541,959 and the highest revenue forecast at $1,096,051,347.

What is QNRX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: QNRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 106.33%.

What is QNRX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: QNRX) Quoin Pharmaceuticals's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that QNRX's EPS will be -$21.58 for 2025, with the lowest EPS forecast at -$25.76, and the highest EPS forecast at -$12.18. On average, analysts forecast that QNRX's EPS will be -$15.74 for 2026, with the lowest EPS forecast at -$24.80, and the highest EPS forecast at -$5.83. In 2027, QNRX's EPS is forecast to hit -$9.97 (min: -$9.57, max: -$10.26).

What is QNRX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: QNRX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.